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Primary Immunodeficiency (PIDs) categorize a broad and heterogeneous group of inborn 
immunity errors. Despite being generally quite rare, PIDs collectively account for consistent 
morbidity and mortality. Currently, more than 350 monogenic PIDs have been recognised to 
embody clinical phenotypes ranging from life-threatening infections to autoimmune/inflammatory 
diseases, allergies and/or malignancy. Many PIDs display genetic and allelic heterogeneity with 
an overlap of symptoms among different syndromes, often making diagnoses challenging. 
In the past few years, advancements in genomic technologies have revolutionised the world of 
genetic testing, and currently, next-generation sequencing (NGS)-based approaches are widely 
applied to routine genetic diagnostics of human disorders. Among the different methods, whole-
exome sequencing (WES) proved highly efficient in revealing the genetic variants behind rare 
disorders. Despite only targeting the coding region of the genome, WES covers the largest share 
of causal variants in severe monogenic diseases.   
To further depict the genetics of PIDs, a WES-based approach was carried out, targeting the 
possible disease-causing variants in Finnish subjects lacking a clinical diagnosis. The cohort 
included patients with a clinical suspicion of immune or/and haematological disorders (n= 212). 
The wide spectrum of phenotypes included severe early-onset disorders (e.g. severe compound 
immunodeficiency, SCID), known PIDs (e.g. antibody deficiency or telomere biology disorders, 
TBDs) and clinically undiagnosed conditions.  
In the first study, a Finnish founder mutation in the AICDA gene was identified in patients 
affected by hyper-IgM syndrome type 2 (HIGM2). The disease is a primary antibody deficiency 
characterised by early-onset recurrent infections, autoimmunity and an absence/low levels of IgG, 
IgA and IgE but elevated/normal levels of IgM. The retrieved ancestral founder allele is 
significantly enriched in Finns compared to other European populations (38.56-fold) and has 
accounted for all HIGM2 cases diagnosed in Finns thus far. 
In the second study, biallelic ADA2 mutations that cause a deficiency of adenosine deaminase 
2 (DADA2) were identified in seven PID patients, all sharing one of the causal variants, which 
were significantly enriched in Finns (3.31-fold). DADA2 was originally associated with systemic 
autoinflammation, polyarteritis nodosa-type vasculitis and mild immunodeficiency. Only a 
fraction of the identified DADA2 patients presented with vasculopathies. In addition, recurrent 
haematological manifestations are noted, and for the first time, the occurrence of 
lymphoproliferation is described for some of the patients, expanding the phenotypic spectrum of 
DADA2.  
Finally, novel causal variants in telomere biology disorders (TBDs)-associated genes (DKC1, 
TERT and RTEL1) were identified in three families with heterogeneous phenotypes that lacked the 
classic clinical pathognomonic signs of telomeropathies. The phenotypes ranged from mild signs 
of Dyskeratosis congenita (DKC) to SCID. The genetic diagnosis was confirmed by an assessment 
of shortened telomere lengths in patients. In addition, the spectrum of TBD-associated phenotypes 
was enlarged, showing variable degrees of cytopenia in some patients.  
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This work attests to the validity of clinical WES testing to identify rare disease-causing variants 
despite the heterogeneous and/or atypical clinical presentations of PIDs. The achievement of a 
genetic diagnosis allowed for updating the spectrum of reported phenotypes as well as including 
atypical clinical presentations that might have otherwise remained undiagnosed. In addition, the 
enrichment of some rare PID-causing mutations in Finland has been depicted, highlighting the 











































In the past two decades, technological breakthroughs in DNA sequencing technologies have 
advanced human genome deciphering, and large-scale genetic diagnostic tests have been 
developed. The current next-generation sequencing (NGS) methodologies have substantially 
increased the sequencing yield and have lowered the cost per base (Buermans et al. 2014). 
Consequently, the possibility to employ high-throughput and cost-efficient DNA sequencing 
strategies has dramatically transformed the diagnostic approach to genetic diseases (Seleman et al. 
2017). Currently, the routine use of NGS-based methods has quickly spread in clinical practices, 
setting the stage for the development of personalised medicine approaches (Rabbani et al. 2014). 
The identification of causal variants in inherited diseases is the outset for either preventive and 
treatment strategies or for terminating the diagnostic odyssey that many patients endure (Jamuar 
et al. 2015). The application of NGS methods in clinical settings varies for different diseases. In 
the field of Mendelian disorders, the increasing use of whole-exome sequencing (WES) and whole-
genome sequencing (WGS) has largely driven the identification of underlying biological 
mechanisms. In particular, providing a suitable balance between costs and sequencing spans, WES 
has emerged as a highly effective strategy for deciphering the genetics of rare diseases (Shen et al. 
2015). 
Rare conditions collectively exert a large burden on society (Dodge et al. 2011; Chong et al. 
2015, von der Lippe et al. 2017). In addition to a large number of affected individuals, diagnostic 
and therapeutic limitations often contribute to a negative impact on patients’ lives and on public 
health resources. The low prevalence of many Mendelian conditions reduces awareness and 
knowledge among healthcare professionals as well as society (von der Lippe et al. 2017). 
Moreover, the clinical description of novel syndromes could be biased by their low prevalence, 
potentially reducing the coverage of the phenotypic spectrum and the potential to identify 
individuals with overlapping features. In addition to prevalence-related issues, Mendelian 
disorders are often characterised by genetic and allelic heterogeneity and an overlap of symptoms 
among different conditions, which can make diagnostic outcomes challenging. Additional 
challenges emerge due to population migrations because conditions once considered rare or linked 
only to specific ethnic groups have been identified in clinics (Dodge et al. 2011).  
Primary immunodeficiencies (PIDs) comprise the heterogeneous spectrum of alterations of the 
development and/or functions of the immune system. The degree of severity of the disorders varies 
considerably, but PIDs collectively cause consistent morbidity and mortality. The burden of PIDs 
on the society is further increased by the diagnostic hurdles that typically result from tackling 
heterogeneous clinical phenotypes (Bousfiha et al. 2013, Seleman et al. 2017). In the era of NGS, 
the number of described PIDs has increased, and there are current descriptions of over 350 
individual conditions linked to alterations in more than 350 genes (Picard et al. 2018). Nonetheless, 
not all the molecular defects that cause PIDs have been identified, and the phenotypic spectra of 
numerous syndromes remain only partially known. Recent estimations suggest that PIDs are even 
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more prevalent than assumed, highlighting the need for the improvement of management strategies 
provided by public health systems (Bousfiha et al. 2013). 
The aim of the study was to elucidate the genetic bases of immune and/or haematological 
conditions overlapping PIDs in Finnish individuals who lacked a conclusive diagnosis. Therefore, 
WES-based methods were applied for the routine diagnostics of potential PIDs. The identification 
of PID-causing variants could reduce challenges typically related to the diagnostic procedures of 
several rare syndromes. Moreover, implementing the genotype-phenotype correlation in rare PID 
entities and determining the distribution of rare detrimental variants in Finland can allow for 















































2 REVIEW OF LITERATURE 
 
2.1 The human genome 
2.1.1 Structure  
The human genome is comprised of nuclear and mitochondrial deoxyribonucleic acid (DNA) 
sequences. Respectively formed by over three billion DNA base-pairs (bp) contained in the cellular 
nuclei and 16,6 DNA kilobases (kb) within the mitochondria, the overall DNA sequence carries 
intrinsic information of human biology.  
At the molecular level, DNA is composed of two strands coiled around each other in the shape 
of a double helix. Each strand consists of multiple basic units defined as nucleotides, which consist 
of a deoxyribose-phosphate backbone and one of the four nitrogenous bases. When forming a 
double-helix, the bases on adjacent poly-nucleotide chains pair reciprocally (adenosine [A] with 
thymine [T] and cytosine [C] with guanine [G]).  
DNA chains are organised into complexes with proteins defined histones. The resulting 
chromatin is tightly packaged in increasing levels of complexity, from nucleosomes (DNA 
segments of ~150bp are wrapped around eight histones) to highly-coiled sub-cellular chromosomal 
structures (Figure 1). The nuclear genome is organised into 23 pairs of chromosomes (22 
autosomes and one pair of sex chromosomes, X and Y) due to its diploid nature because a copy of 
the genome (haploid) is inherited from each parent. The mitochondrial genome is more simply 











Functionally, DNA sequence elements are organised into segments displaying a specific 
biochemical function, also defined as coding regions (protein or non-coding RNA) (ENCODE 
Project Consortium, 2012). Among functional genomics, unit protein-coding genes have been the 
most extensively studied and are estimated to total 20.000-25.000 (Ezkurdia et al. 2014). The 
expression of protein-coding genes is controlled in eukaryotic organisms by complex regulatory 
mechanisms layered on hierarchical levels, ascribable to the transcription of individual coding 
units, the structural organisation of chromatin and the epigenetic regulation of gene expression 
(van Driel et al. 2003).  
The completion of the Human Genome Project over a decade ago represented a turning point 
for genetic and genomic studies. The resulting first complete draft of the reference genome 
sequence allowed for establishing baselines for comparisons with the sequence data generated by 
following individual re-sequencing studies (Lander et al. 2001, International Human Genome 
Sequencing Consortium, 2004). Afterward, a succession of large-scale genotyping and sequencing 
efforts produced data included in publicly available registers of population-level human variations 
(e.g. The 1000 Genomes Project Consortium, 2015; Exome Variant Server: the Exome 
Aggregation Consortium, ExAC, 2016; the Genome Aggregation Database 2016, gnomAD, Lek 
et al. 2016). This increasing volume of data has supported population genetics studies, and it 
contributes to the continuous process of deciphering the features of genetic variations, especially 
related to human diseases. 
2.1.2 Variation 
All humans share a full sequence identity for about 99,9% of their genomes (Venter et al. 2001). 
The remaining 0,1% of the sequence variation could contribute to shaping the differences among 
individuals along with environmental factors. Any difference in sequence among the (consensus) 
reference genome and the nucleotide sequences generated by subsequent genomic studies is 
considered as genetic variant. A genetic variation is determined by permanent changes in the DNA 
sequence of a genome. It can occur in different forms and can involve different regions of the 
genome with different extent, if any, on human phenotypes. In addition to homologous genetic 
recombination (occurring during meiosis), sequence changes arise in the genome through mutation 
processes. Mutations can be spontaneous, such as through ensuing errors in DNA replication or 
repair processes or can be induced by environmental factors (e.g. chemicals, radiations).  
Overall, mutation frequency is not uniform along the genome due to mutational properties 
and/or selective pressures (Hastings et al.1991; Nachman et al. 2000; Tiemann-Boege et al. 2002; 
Goriely et al. 2003; Choi et al. 2008; Qin et al. 2007; Arnheim et al. 2009). Certain nucleotide 
positions, defined as mutation ‘hotspots’, were shown to be more prone to variations, and a higher 
rate of variation often reflects specific nucleotide-sequence features, such as repetitive sequences 
(e.g. homonucleotide runs, microsatellites) or CG-dinucleotide rich regions (CpG sites) (Rogozin 
et al. 2003; Kong et al. 2012).  
Genetic variation can be viewed from the nucleotide-level or the chromosome-level 
perspective. The changes at the nucleotide level, namely the monomers of DNA strands, are 
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defined as single-nucleotide variants (SNVs). Small insertions or deletions (indels) represent gains 
or losses of genetic sequences usually smaller than 50bp, while structural variations (SVs) include 
larger differences (even ≥1kb). Copy-number variants (CNVs) are duplications or deletions of 
DNA segments, which are present in a number of copies different than the reference. Other 
macroscopic forms of structural variations can affect the number and/or the genetic content of one 
or more chromosomes. Based on the number, SNVs represent the largest category of variations, 
taking place on average each 8bp within the exonic regions according to updated estimates (The 
1000 Genomes Project Consortium 2015; Lek et al. 2016).  
From a technical perspective, the detection of some forms of variations remains problematic, 
including small CNVs (<500bp), the insertion of sequences different from the reference, subtle 
variations in the number of copies, highly-represented dispersed repeats (e.g.  Alu elements, 
LINEs) and CNVs located on the Y chromosome or heterochromatic regions (Wheeler et al. 2008; 
Conrad et al. 2010).   
 
2.2 Genetic variations in human diseases 
Any individual human genome presents an estimated amount of ~4,1-5 million variation sites in 
comparison to the reference. This variation load is mostly (>99,9%) represented by SNVs and 
short indels (Figure 2) (The 1000 Genomes Project Consortium 2015). Overall, more than 100 
million variants have been listed in the dbSNP database of human sequence variations (Sherry et 
al. 2001; The 1000 Genomes Project Consortium 2015). Recent large-scale sequencing projects 
provided a broader view of existing genomic variability, showing a significant quote to be tolerated 
or not linked at any rate to (manifest) deleterious effects (The 1000 Genomes Project Consortium 
2015; Lek et al. 2016). A fraction of the depicted genetic variations could result from positive 
selection due to beneficial evolutionary effects, but not all genetic variants are neutral or are not 
linked to any phenotypic effect.  
Currently, according to the Online Mendelian Inheritance in the Man OMIM® database 
(https://omim.org/; Hamosh et al. 2005), variants in 3874 genes are linked to more than 6000 
clinical phenotypes, including both single-gene Mendelian disorders and susceptibilities to cancer 
and complex diseases. Focusing on the disease-associated variants, ~180.000 entries are listed in 
the Human Gene Mutation Database (HGMD®) (Krawczak et al. 1997).   
The effect of mutations occurring in a genome can be evaluated at the evolutionary level as 
neutral, beneficial or deleterious based on the effects of the nucleotide changes on the resultant 
gene products. If the function of the gene product is abolished, the causing-variants are defined as 
loss-of-function (LoF) or hypomorphic if the repercussion is only partial. A dominant-negative 
effect occurs when the mutated product can affect the wild-type product at the functional level. 
Other variants can result in aberrant or heightened activity, causing the so-called gain-of-function 
(GoF) effect.  
If the variants occur in protein-coding genes, their consequences can be evaluated on the 
resulting protein structure. Variants that do not alter the amino acid sequence are defined as silent 
(or synonymous). If the result is instead the substitution of one amino acid with a different one, 
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the variants are defined as missense (or non-synonymous). Different type of variants which could 
result in reduced or abolished protein function, defined as nonsense (introduction of a premature 
stop codon), splice site (removing physiological splice sites or inserting aberrant ones) or 
frameshift indels (interruption of the amino acid sequence reading frame) can be grouped in the 
category of LoF. Indels that do not induce frameshifts (e.g. inserting or deleting triplets of 
nucleotides) are defined as in-frame. In addition to the inherited variation, de novo mutations can 
play a significant role in disease pathogenesis. De novo mutations manifest without apparent 
parental inheritance, either arising in the germ cell of one of the parents or in the fertilised egg 
during early embryogenesis, with an overall estimated frequency of 1,5×10−8 SNVs per site 
(Turner et al. 2017). When de novo mutations occur after conception in cell lines other than the 
germline, they are defined as somatic, and only that specific cell population will carry it. Somatic 







Figure 2. Consequences of point mutations (SNVs) on the protein. 
 
2.3 Genetics of rare disorders 
Rare genetic diseases are medical conditions that affect a small fraction of the population. 
According to the European classification, a disease is labelled rare if it affects less than one 
individual of 2000 (http://www.orpha.net/consor/cgi-bin/index.php, May 2017), while in the US, 
it is rare if the total of affected patients is less than 200.000 (http://www.fda.gov, May 2017) 
(Pogue et al. 2017). Despite being in general quite rare, Mendelian diseases collectively exert a 
large burden on public health due to the large number of patients affected. A total of 6000-8000 
mostly Mendelian (or monogenic) rare diseases have been estimated. Altogether, over 30 million 
people in Europe and 25 million in the US suffer from severe and/or chronic manifestations of 
Mendelian conditions, often with absent or limited treatment options (Haffner et al. 2002; Dodge 
et al. 2011; von der Lippe et al. 2017). 
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The limited number of described clinical cases reduces knowledge both at the professional and 
at the society level, resulting in long, erroneous and/or inconclusive diagnostic procedures. 
Moreover, the more severe phenotypes are detected first, usually having a greater contribution to 
the description of disease-associated phenotypes and potentially hindering future correlations with 
milder traits. In addition, the diagnostic process could be deceptive in the presence of novel genetic 
causes that are not targeted by the genetic tests. Along with low prevalence-related issues, the 
overlap of clinical symptoms among different conditions and the high genetic heterogeneity 
reported can further complicate the diagnosis of rare diseases.  
From a genetic perspective, rare disorders are mostly caused by fully-penetrant single-gene 
alterations, with (coding-) mutations in over 3000 genes previously disclosed (Table 1, McKusick 
et al. 2007). According to the Mendelian segregation, the phenotypes can be inherited with 
autosomal-recessive, autosomal-dominant or X-linked recessive patterns. Alternatively, in case of 
incomplete penetrance the disease-causing variants can be inherited from apparently unaffected 
parents. Recessive disorders are mostly caused by LoF or hypomorphic variants, while dominant 
disorders are mostly due to GoF and dominant-negative variants. X-linked recessive disorders 
manifest only in male individuals harbouring one copy of the causative variant, although in some 
cases mild symptoms can be observed in female carriers.  
Recent population-level sequencing studies showed an uneven load of potentially detrimental 
variants (LoF, missense) across distinct genes, suggesting that different degrees of selection can 
determine the shift from the estimated mutation rate (Lek et al. 2016). Accordingly, disease-
causing genes have been shown as less tolerant to functional genetic variations than others not 
associated with any known disease (Petrowski et al. 2013). 
 
   
Phenotypes with known molecular basis* 6,153 
Genes with phenotype-causing mutation 3874 
Genes linked to 1 phenotype 2,652 
Genes linked to 2 phenotypes 729 
Genes linked to 3 phenotypes 259 
Genes linked to 4 or more phenotypes 234 
 
 
Table 1. Gene statistics from the Online Mendelian Inheritance in the Man OMIM® database (https://omim.org/) (updated January 31st, 
2018).  
*Phenotypes including single-gene Mendelian disorders and traits, susceptibilities to cancer and complex disease variations that lead to abnormal 
but benign laboratory test values (‘non-diseases’) and blood groups. 
 
2.4 Genetic testing in Mendelian diseases 
Given their mostly monogenic aetiology, Mendelian disorders have always represented a forefront 
for genetic association studies, and thus far, 3874 genes have been linked to rare monogenic 
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syndromes (http://www.orpha.net/consor/cgi-bin/index.php, May 2017). Understanding the 
genetic bases of rare diseases can improve the clinical practices, and the genes-phenotypes 
correlation can shed light on the biological mechanisms underlying clinical conditions (Figure 3; 
Dodge et al. 2011). Nonetheless, the low prevalence of Mendelian disorders has always 
represented an obstacle to identifying the causes. Another limitation is genetic heterogeneity, 
which has recently been shown to reduce the diagnostic rates (Chong et al. 2015). Deciphering the 
molecular bases of Mendelian disorders can enable discerning distinct conditions not previously 
recognised as single entities and that have been included in more complex phenotypes, thus 
reducing the difficulties that patients experience as well as difficulties related to medical practices 




Figure 3. The link between protein-coding genes (~19,000) and Mendelian phenotypes (~3,000). Adapted from Chong et al. (2015). 
 
Beginning in the 1980s, the discovery of genes associated with Mendelian disorders resulted 
from indirect positional cloning and genome-wide linkage analyses or candidate-gene approaches 
(Figure 4, Chong et al. 2015). If candidate-gene approaches clearly rely on previous biological 
assumptions, the main constraint of positional cloning occurs due to the limitation of familial traits 
with many affected members, therefore neglecting rare sporadic cases. In addition, the genetic 
heterogeneity of Mendelian diseases is a disadvantage for linkage studies, which have typically 
been more successful in populations presenting a reduced load of genetic variations, such as the 
Finnish isolate (Peltonen et al. 1998). After indirect methods were used for two decades, Sanger 
sequencing represented the standard method for Mendelian disease testing, allowing for the 
analysis of single genes (or sections of them) with high accuracy (Sanger et al. 1975). However, 
this approach is expensive and laborious if applied to multiple or larger targets, which is required 
for genetic heterogeneous disorders.  
Technological breakthroughs over the past decade have resulted in drastic improvements of 
genetic testing methods, increasing the content and automation level of sequencing processes while 
reducing the cost per base. This progress is generically attributed to next-generation sequencing 
(NGS). Introduced in 2005, NGS-based methods have revolutionised the field of gene discovery, 
allowing for parallel sequencing of multiple genes, the whole protein-coding region (whole-exome 
sequencing, WES) or genomes (whole-genome sequencing, WGS) (Jamuar et al. 2015). The ever-
increasing use of WES and WGS has dramatically advanced the identification of the genetic causes 
of Mendelian phenotypes (Chong et al. 2015). Given the impact of DNA sequencing, the 
development of personalised medicinal approaches is expected in upcoming years (Rabbani et al. 
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2014). Nonetheless, the use of NGS is still highly demanding in terms of storing, processing, 





Figure 4. Main advantages and limitations of the most commonly used methods (from the 1980s to the present) for the discovery of genes 
associated with Mendelian disorders.  
 
2.5 Next-generation sequencing applications in the study and diagnostics 
of rare diseases 
The identification of disease-causing variants provides support for diagnostic, preventive and 
therapeutic strategies. Consequently, the use of NGS-based methods has increased in clinical 
settings despite the associated drawbacks, namely high costs and analytical and ethical issues 
related to the generated genetic data (Jamuar et al. 2015) (Figure 5). A crucial aspect of the 
adoption of NGS is the selection of the different testing applications that are most relevant to the 
specific diagnostic requirements. Gene-panels (targeted sequencing), WGS and WES are among 
the most widely adopted methods in clinical genetics.  
Targeted approaches are applied to clinical phenotypes suggestive of a specific genetic 
aetiology according to the so-called ‘phenotype first’ approach. The targeted genes (scaling up to 
hundreds) are probed using panels, generally screening only the coding sequence of the candidates. 
In specific cases, the coverage of the disease-target genes can be integrated using complementary 
technologies (i.e. Sanger sequencing, long range PCR) (Jamuar et al. 2015). Targeted approaches 
are time- and cost-effective due to the low yield of generated data. In addition, the coverage of the 
established disease-causing genes is higher than for WES (Oishi et al. 2014). On the other hand, 
main limitations of targeted approaches lie in the reliability of the (established) genotype-
phenotype correlations and in the needs of expert and accurate phenotype recognition. Other 
downsides involve limitations in deciphering genetically heterogeneous conditions and in 
identifying new disease genes. 
WGS creates the possibility to identify variants genome-wide without requiring target selection 
or enrichment strategies. Compared with other NGS-based methods, WGS provides more uniform 
coverage and produces the highest diagnostic yield including genomics or variations outside the 
reach of WES (intronic, noncoding RNA genes, small CNVs, exonic SNVs due to WES coverage 
and enrichment issues). However, the limitations still include the increased cost and the demanding 
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requirements for data analysis, interpretation and storage (Lionel et al. 2017). Because the cost of 
WGS still prevents its routine application in diagnostic setups, WES currently represents an 
effective method to investigate the coding regions of a genome, and it is widely adopted in research 
and diagnostic contexts (Rabbani et al. 2014). Targeting only about 1% of the human genome, 
WES has become the most cost-effective approach because the largest part of the currently 
identified Mendelian phenotypes has originated from coding-sequence alterations (Chong et al. 
2015; Shen et al. 2015). In addition to the discovery of novel disease-causing genes, WES can 
successfully identify causative variants in heterogeneous disorders (Rabbani et al. 2014). 
Nonetheless, despite targeting whole protein-coding regions, comprehensive WES coverage 
estimates are between 85–95%, indicating a potential lack or incomplete coverage of phenotype-
related genes (Jamuar et al. 2015). Moreover, technical limitations and/or specific genomic 
features (e.g. repetitive sequences, homopolymers, high-GC content) could hamper the uniformity 
and the average coverage of the targeted exome.   
WES and WGS can be used as ‘genotype first’ approaches in which a diagnosis can be 
established based on the molecular findings without any previous hypothesis or acknowledgment 
of the biological implication(s) of the disease-causing gene(s). The ‘hypothesis-free’ approach 
allows for detecting disease-causing mutations in cases of clinical presentations that do not 






Figure 5. Genetic diagnostics flowchart before and at the time of next-generation sequencing.  
 
2.6 Sequencing and processing of the obtained data 
In the analytic phase of NGS, sequences are generated and analysed as depicted in Figure 6. The 
analysis of NGS data requires significant bioinformatics and computational processing, usually 
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enclosed in informatics pipelines designed and tailored based on their clinical applications. 
Currently, a large set of public or in-house software tools is available to process sequencing data, 
of which the Genome Analysis Toolkit (GATK) represents one of the most widely used in research 





Figure 6. Flowchart of NGS-data generation and bioinformatics analysis.  
  
 
2.6.1 Sequence data generation and processing 
Prior to sequence generation, the template material is used to generate a ‘library’ of size-selected 
DNA fragments. For targeted or WES analyses, it is necessary to capture or enrich the region of 
interest (ROI) to enable the sequencing process. No enrichment is required for WGS. The use of 
library-specific oligonucleotide labels (tag or index) allows for labelling each fragment with the 
patient-specific specimen, permitting the analysis of multiple sample libraries simultaneously 
(multiplexing).  
Following library generation, the clonal amplification of the DNA fragments and massive 
parallel sequencing are performed. The base-calling processes generate digital representations of 
short nucleotide sequences defined as ‘reads’, whose quality is controlled after the base-calling 
process according to the criteria established in each sequencing centre. In the following stages, the 
sequencing reads are mapped and aligned to the genome for the identification of sequence variants. 
The mapping quality of each read is assessed, and any read pair or single read mapped to multiple 
genomic positions is removed. Next, the refinement of the alignment of read mapping in the 
proximity of indels sites and the removal of any potential PCR-resulting bias (duplicate reads) are 
performed.  
2.6.2 Detection of sequence variants 
The major tasks involved in NGS are the accurate detection of SNVs and small indels located in 
the ROI, and distinguishing between true variants and sequencing or analytic errors. Therefore, 
after alignment, the coverage over the ROI and the quality of the whole process are assessed. To 
ensure high accuracy, a coverage threshold can be used to recalculate the resulting variants 
according to the quality values. Variant calling involves multi-step processes that can generally be 
performed by a variety of tools. A recent comparison of different methods suggested the joint use 
of both GATK and SAMtools to improve variant detection during a WES analysis of human 
diseases (Kim et al. 2017).  GATK is an assortment of tools used for the analysis of genomic data, 
which was developed and released by the Broad Institute (McKenna et al. 2010). The GATK 
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variant calling process utilises the HaplotyperCaller tool (DePristo et al. 2011). SAMtools is used 
to process SAM and BAM files originated by alignment processes. It includes BCFtools, which 
contains utilities for variant calling processes (Li et al. 2009). Because the accurate calling of 
indels still presents challenges, additional programmes are available for detection. Dindel is a tool 
specifically developed by the Wellcome Trust Sanger Institute for the detection of indels (Albers 
et al. 2011). 
2.6.3 Variant annotation 
Variant calling processes result in a list of individual genotypes that differ from the reference 
genome. The amount of genetic information produced depends on the different sequencing 
platforms and pipelines used for data generation and analysis. The next stage involves the 
interpretation of the clinical significance of the detected variants. To manage the (usually) large 
list of variations generated, several computer-based annotation programmes allow for the 
prioritisation and filtering of potential causal variants. A common approach is linking the retrieved 
variants to information from genetic variation public databases (Pabinger et al. 2014).  
To interpret causal variants, it is important to determine whether they are located in coding 
genes and whether they potentially affect the encoded products. Annotation programmes are 
usually used to mine gene- and population-level data as well as disease-specific information. 
Different predictions of the functional consequences caused by variants can result from different 
approaches, including sequence- and region-based analyses and the evaluation of the resulting 
structure of the affected protein. The predictions are used to classify the variants based on their 
supposed deleteriousness (DePristo et al. 2011). In addition, recent massive sequencing efforts 
released publicly available registers of population-level human variations (see paragraph 2.1.1), 
which allows for discarding a large part of the retrieved variants. Each application for variant 
annotation refers to one or multiple gene annotation sets (RefSeq and Ensembl among the most 
common). Several annotation tools can be used as applications without the need to install them on 
local machines (Pabinger et al. 2014). Among the many tools available, ANNOVAR is one of the 
most widely adopted tools for annotations and for predictions of the functional consequences of 
the identified variants (Wang et al. 2014; Chang et al. 2012). 
 
 
2.7 Interpretation of sequencing results and identification of disease-
causing variants 
 
2.7.1 Filtering of whole-exome sequencing data 
Regardless of the application used, NGS generates a number of variants which can exceed the 
analytic possibility of the users. Filtering processes are therefore applied to reduce the number of 
variants for further rounds of analysis. These processes are modulated based on the disease features 
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and the analytic plans of the executing laboratories (Figure 7). The first selection criterion for 
variant filtering is the effect on the resulting gene product. Non-coding (inter-genic or intronic) 
variants are typically discarded, and nonsense, missense, synonymous, splice site SNVs and indels 
are included instead. A large part of the remaining variants is pruned by filtering based on the 
population frequency. The variants that are common in the general population are usually 
discarded. The threshold for the allelic frequency is established according to the estimated 
inheritance pattern, the disease frequency and/or the expected disease allele frequency. Usually, 
the set is 0,01 for recessive diseases and lower for dominant ones. To date, the largest available 
register of population-level human variations is the Genome Aggregation Database (gnomAD, 
2016, Lek et al. 2016).  
The prioritisation process of causal variants continues based on reported links with possible 
phenotypic effects. For example, established sources of gene-disease information are OMIM® and 
the Human Gene Mutation Database (HGMD®) (Krawczak et al. 1997; Hamosh et al. 2005). 
Additional filtering can be performed based on the assumed inheritance pattern or phenotype 






Figure 7. Filtering steps of whole-exome sequencing data to search for the disease-causing variant(s). 
Panel A shows the filtering steps based on the quality and the consequences of the retrieved variants. Panel B lists the filtering applied in the 
function of assumed (or inferred) recessive or dominant (and de novo) inheritance patterns. The typical number of variants retrieved is based on the 






Figure 8. Whole-exome sequencing-based approach for gene identification in rare disorders. Adapted from Boycott et al. (2013). 
The panels show pedigrees exemplary for different segregation patterns of rare diseases. Male individuals are indicated by squares and females by 
circles. Purple-coloured symbols specify affected individuals, while dots in the squares/circles indicate the carriers of a rare disease-causing 
mutation. Stars in the circles below the pedigrees indicate the range in which the possible disease-causing mutations are searched. The selection of 
the appropriate strategies for disease-gene identification is based on the expected mode of inheritance of the disease variants, whether the mutations 
are inherited, de novo or mosaic.  
A. Research of inherited disease-causing variants. For autosomal recessive disorders, the analysis of affected sib pairs (if available) helps 
reduce the number of candidate gene variants, even in consanguineous families. For X-linked recessive diseases, the analysis of the most 
remotely related male family members is the most effective strategy.  
B. The trio-approach utilises data from unaffected parents and affected children, allowing for monitoring de novo variants.  
C. The identification of de novo mosaic disease-causing variants requires a comparison of sequence data from affected and unaffected tissues 
in the same individuals. 
 
2.7.2 Estimation of variant deleteriousness 
Given the large output of WES and WGS, the clinical interpretation of genetic variants represents 
a crucial stage of the analytic process. Recent studies have indicated an unexpectedly large number 
of erroneously reported disease-causing mutations. Twenty-seven per cent of 460 causal variants 
cited were instead common polymorphisms or sequencing errors, or they lacked evidence of 
pathogenicity (Bell et al. 2002). More recently, a large-scale population study showed that on 
average, WES can retrieve ~54 variants in all individuals previously recorded as disease-causing 
variants. Most of these inconsistencies are due to classification errors in the literature and/or 
catalogues or databases of human variations (Lek et al. 2016). 
In an effort to improve and standardise the quality of clinical interpretations of genetic variants, 
the American College of Medical Genetics and Genomics (ACMG) released specific guidelines 
(Richards et al. 2015). A series of criteria (inclusive of gene- and population-level information and 
in silico prediction tools) can be used to portray the pathogenicity of variants based on the structure 
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and the evolutionary conservation of the affected protein/domain/residue. The resulting five-level 
scale ranges from benign to pathogenic, with the variants of unknown significance being among 
the most difficult to interpret.  
According to these criteria, the most straightforward interpretation follows the identification 
of reported disease-associated variant(s). To establish a causal relation, the patient’s phenotype 
and the inferred inheritance patterns of the candidate variant must match those associated with the 
gene. The interpretation process is more complex if the retrieved variant(s) are not previously 
reported but are in known disease genes. In this case, the overlap of phenotypic features with what 
is reported in the literature or the segregation data is not sufficient to confirm the genetic findings 
as causal. In silico programmes can be used to support the potential causative role of the variants 
and to prioritise candidate pathogenic novel variants. Nonetheless, they can’t be considered a 
replacement for functional validations and have not yet achieved enough accuracy to be used in a 
clinical setup (Young et al. 2015; Seifi et al. 2018). Therefore, establishing whether an identified 
genomic variant could be causative or could determine medically actionable conditions remain a 




2.8 Primary Immunodeficiency  
 
2.8.1 Overview 
Primary Immunodeficiency (PIDs) comprise a large and heterogeneous spectrum of monogenic 
germline disorders that affect the development and/or functions of the immune system. Despite 
being generally quite rare, the global frequency of PIDs is estimated to be around 1:1200 live 
births, and the reported incidence is likely underestimated due to the difficulties in diagnosing 
patients with atypical clinical presentations (Bousfiha et al. 2013; Seleman et al. 2017). The 
classification of PIDs is generally based on their clinical characteristics. Usually, an initial clinical 
categorisation of PID suspects is proposed along with targeted screening tests to determine any 
likely causative genetic defects to select diagnostic therapeutic strategies (Seleman et al. 2017). 
Nonetheless, the presented approach can be time-consuming and expensive, especially if applied 
to heterogeneous and/or elusive phenotypes.   
The introduction of NGS technologies has allowed for targeting multiple genes in synchrony, 
setting the stage for the development of extensive molecular diagnostic tests (Seleman et al. 2017). 
Due to the emergence of NGS applications in diagnostics and research, the number of recognised 
PIDs swiftly increased. To date, alterations in 344 different genes have been reported in association 
with more than 350 distinct conditions (Picard et al. 2015, 2018). Due to improved molecular 
diagnostics, the phenotypic spectrum associated with several individual diseases was extended. 
The broad variability identified in many individual PIDs reflect allelic heterogeneity and/or 
host/environmental modifying factors (Picard et al. 2015).  
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The spectrum and prevalence of PIDs in Finland have only been partially characterised. 
Recently, a cross-sectional study depicted an unprecedented high prevalence of Common Variable 
Immunodeficiency (CVID) in the Finnish population. CVID represents the most prevalent PID 
worldwide (2-4/100000), and the enrichment in Finland (6,9/100.000) is likely determined by the 
unique feature of the population (Selenius et al. 2017).  
The population history of Finland has in fact led to a phenomenon defined as the Finnish 
Disease Heritage (FDH), distinguished by the enrichment of some detrimental disease-causing 
variants and a loss of others. The resulting FDH disorders are more frequent in Finland than 
elsewhere. For each of the FDH disorders, most (or all) of the affected individuals are identified 
by a causative founder mutation (Finmajor), displaying allelic frequencies higher in Finland than in 
other populations (Peltonen et al. 1999; Norio et al. 2003). Thus far, three PIDs have been included 
in the FDH: cartilage-hair hypoplasia (CHH), autoimmune polyendocrinopathy (APECED) and 
Cohen syndrome (Neufeld et al. 1981; Makitie et al. 1992; Ridanpaa et al. 2001; Norio 2003; Polvi 
et al. 2013). The currently available population-level exome data show two Finmajor mutations 
significantly more frequent in Finns than in other populations with European ancestries. The 
mutations cause APECED (rs121434254, 6.25-fold enriched) and Cohen syndrome (rs180177327, 
47.11-fold), respectively. No reliable data are available for CHH-associated variants. 
 
2.8.2 Disease classification 
The classification of PIDs is performed, revised and implemented since 1990 by the Primary 
Immunodeficiency Expert Committee (PID EC) of the International Union of Immunological 
Societies (IUIS) and joint task forces, ), now named Inborn Errors of Immunity Committee (Al-
Herz et al. 2014; Bonilla et al. 2015; Picard et al. 2015, 2018, Bousfiha et al. 2018). These 
catalogues of inborn errors of immunity served as a reference for immunologists and researchers 























I. Immunodeficiencies affecting cellular and humoral immunity 
Caused by defects in T- and B-cells, these immunodeficiencies most often cause increased susceptibility to infections (bacterial or 
viral), at times with autoimmune manifestations. 
II. Combined immunodeficiencies with associated or syndromic features 
Conditions with distinguished phenotypes inclusive of immune defects. 
III. Predominantly antibody deficiencies 
This group accounts for approximately half of all patients with a PID diagnosis. 
IV. Diseases of immune dysregulation 
These diseases are caused by a defective control of the adaptive immunity, often characterised by autoimmunity and/or 
haematological malignancies. 
V. Congenital defects of phagocyte number or function 
These defects are caused by a severe reduction in the number or function of phagocytes. 
VI. Defects in intrinsic and innate immunity 
This category includes conditions determined by defects in components of the innate immunity, usually associated with isolated 
susceptibility to specific pathogens. 
VII. Autoinflammatory disorders 
This is a group of conditions causing (recurrent) febrile episodes characterised by inflammatory manifestations (cutaneous, mucosal, 
serosal and osteoarticular) (Fietta et al. 2004; Zeft et al. 2012; Ozkurede et al. 2012). 
VIII. Complement deficiencies 
These deficiencies are associated with varied clinical manifestations related to the altered branch(-es) of a pathway. 
IX. Phenocopies of inborn errors of immunity 
These errors are diagnostic relevant non-inborn errors of immunity resembling inherited PIDs (Picard et al. 2018). 
 
 
Table 2. Revised 2017 phenotypic classification of inborn errors of immunity. 
Based on the accompanying 2017 IUIS Inborn Errors of Immunity Committee classification (Bousfiha et al. (2018) 
2.8.3 Autosomal recessive hyper-IgM syndrome type 2 
Hyper-IgM syndromes (HIGM) are rare PIDs characterised by early-onset recurrent infections 
with autoimmunity, also referred to as Immunoglobulin class switch recombination deficiencies 
(CSR-D). The typical immunological trait of HIGM type 2 (HIGM2) is the absence or very low 
levels of IgG, IgA and IgE along with elevated or normal serum IgM levels (Gulino et al. 2003). 
The clinical hallmark of HIGM is lymphadenopathy, mostly in cervical and mesenteric lymph 
nodes as described in the majority of patients (75%). Histological sections of the massively 
enlarged lymph nodes portray a notable follicular hyperplasia with giant germinal centres (GC) 
(Zeft et al. 2012). The phenotypes typically reflect causal defects in some of the proteins involved 
in class switch recombination (CSR) causing a flawed process of somatic hypermutation (SHM) 
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in the Ig variable (V) region, which represents a crucial stage for antibody (Ab) functionality 
(Figure 9). CSR-Ds are genetically heterogeneous due to the possibility of alterations in different 
pathways related to antibody maturation (e.g. B cell activation, the formation of GC, induction of 
CSR, CSR and SHM processes) (Durandy et al. 2013).  
      Known established Ig-CSR deficiency causing genes include CD40, CD40LG, AICDA and 
UNG (Durandy et al. 2007). CD40L/CD40-deficiencies feature defects in cellular immunity, 
determining susceptibility to opportunistic and viral infections that are not dependent on 
immunoglobulin responses (Revy et al. 1998). For other CSR-Ds, recurrent bacterial infections, 
mostly in the gastrointestinal and respiratory tracts, are instead determined by humoral immunity 
defects caused by altered CSR processes. The most common intrinsic B cell defects in CSR-D are 
caused by mutations in AICDA gene encoding for activation-induced cytidine deaminase (AID), 
which is estimated to affect fewer than 2/107 individuals (Durandy et al. 2013; Revy et al.1998; 
Minegishi et al. 2000).  
     The AID function is crucial for the correct implementation of CSR, SHM and central B cell 
tolerance (Kuraoka et al. 2011; Meyers et al. 2011; Cogne et al 2013). In addition, AID participates 
in the removal of epigenetic signatures through active de-methylation (Kumar et al 2013). AID-
deficient patients often present with autoimmunity, increasing the burden of life-threatening 
manifestations in HIGM patients (Quartier et al. 2004; Durandy et al. 2013). Despite the genetic 
heterogeneity of HIGM, AID and uracil DNA glycosylase (UNG) deficiencies cause similar 
immunologic phenotypes. The most relevant feature is the absence of CD19+CD27+IgD-IgM-
switched memory B (smB) cells in the blood, while marginal zone CD19+CD27+IgD+IgM+ B 
(MZB) cells are normal or high. The recognisable features associated with AID and UNG 





Figure 9. AID cytidine deamination activity in B cells. Adapted from Keim et al. (2013). 
AID activity causes the deamination of cytidine residues. The resulting uracil residues are recognised for repair by the DNA base excision repair 
[BER] enzyme uracil DNA glycosylase (UNG) or by mismatch repair [MMR] factors (MSH2/MSH6). Based on the activity of error-prone DNA 
polymerases (DNA pol η), adjacent A/T-based pairs may be mutated to T/A, G/C or C/G base pairs. The uracil residues can also be excised by 
apurinic/apyrimidinic endonucleases (APE1 and APE2), causing single-strand (ss) DNA nicks. ssDNA nicks on both strands can generate DNA 
double-strand breaks (DSBs) during the class switch recombination (CSR) process. 
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2.8.4 Deficiency of adenosine deaminase 2 
In 2014, biallelic deleterious ADA2 (formerly CECR1) mutations were identified in patients 
with rare systemic autoinflammatory conditions characterised by vasculopathy and mild 
immunodeficiency defined as a deficiency of Adenosine deaminase 2 (DADA2). The vasculopathy 
symptoms in DADA2 patients featured primarily early-onset polyarteritis nodosa (PAN) and 
intracranial haemorrhagic and ischemic strokes. The chronic and recurrent systemic inflammation 
manifested with fever (with possible different skin phenotypes) and higher levels of acute phase 
reactants. The immunodeficiency symptoms are mostly similar to hypogammaglobulinemia. 
Overall, the occurrence of ischemic or haemorrhagic cerebral strokes represents the most severe 
manifestation and the primary cause of death for some DADA2 patients (Zhou et al. 2014; Elkan 
et al. 2014). In a zebrafish model, the transient knock-down of the orthologous of the human 
ADA2gene caused intracranial bleeding and severe neutropenia in embryos. The phenotype was 
prevented by a co-injection with wild-type human ADA2 mRNA (van Montfrans et al. 2016). 
Subsequent studies added common variable immunodeficiency (CVID), Blackfan-Diamond 
anaemia, immune dysregulation, spastic paraplegia and bone marrow symptoms to the phenotypic 
spectrum of DADA2 (Table 3, van Montfrans et al. 2016; Hashem et al. 2017; Jain et al. 2017; 
Michniacki et al. 2018). Among the 43% of the patients with haematological manifestations, 
cytopenia symptoms were the most frequent (Table 3). 
Currently, around 150 DADA2 patients have been reported in the literature (Table 3), some 
following clinical DADA2 suspicion while other after WES. All affected patients have been 
deficient in the plasma activity of the ADA2 protein. A large variability in clinical presentation 
and a lack of a clear correlation with ADA2 genotypes emerged from the reported cases (Figure 
10).  
Interestingly, another ADA protein (ADA1) has previously been described in humans, which 
is encoded by the ADA gene. Both ADAs present adenosine deaminase activity (Franco et al. 2007; 
Zavialov et al. 2010). Mutations in ADA have been shown to cause severe combined 
immunodeficiency (SCID) (Buckley 2004). SCIDs are caused by the intracellular accumulation of 
toxic adenosine products resulting in apoptosis, depleting the count of circulating T, B and NK 
lymphocytes (Franco et al. 2007). Despite the similarities, human adenosine deaminases bind to 
distinct lymphocyte subsets that express specific receptors for ADA1 and ADA2 (Kaljas et al. 
2017). In addition to differences in deaminase functions, ADA2 is secreted by activated monocytes 
and determines their proliferation and macrophage differentiation (Zavialov et al. 2010). Thus, a 
possible role of ADA2 in the balance between pro-inflammatory (M1) and anti-inflammatory (M2) 
monocytes has been postulated. In support of this postulation, experimental silencing of ADA2in 
myeloid cells resulted in a reduction of monocytes to macrophage differentiation and a higher 
prevalence of pro-inflammatory (M1) cells (Zhou et al. 2014).  
Diverse therapeutic options have been suggested for DADA2, usually depending on the variety 
and severity of the symptoms in individual patients. Corticosteroids are used for the temporary 
relief of symptoms, and only anti-TNF agents among various immunosuppressants have been 
shown to lead to disease remission in patients with or without vascular lesions (Schepp et al. 2017). 
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Haematopoietic stem cell transplantation (HSCT) can be conceived as a potential definitive option 
in DADA2 (Van Eyck et al. 2015), even in patients with severe haematological and/or 












































Hematologic manifestations BM findings 
Zhou et al. (2014) 6/9 Leukopenia (n=3); Pancytopenia (n=2); Evans syndrome (n=1) 
BM myelofibrosis and 
lymphohistiocytic aggregates (n=1) 
Elkan et al. (2014) 0/24  -   
Garg et al. (2014) 0/1  -   
Belot et al. (2014) 0/2  -   
van Montfrans et al. (2014) 2/2 Lymphopenia (n=1); Granulocytopenia and Anemia (n=1)   
van Eyck et al. (2014, 2015) 1/2 Cytopenia and lymphoproliferation    
van Eyck et al. (2014) 1/1 Anemia    
Bras et al. (2014) 0/5  -   
Westendorp et al. (2015) 0/2  -   
Gonzalez Santiago et al. (2015); 
Abraam et al- (2016) 0/2  -   
Batu et al. (2015) 2/6 Macrophage activation syndrome (n=1). B-cytopenia additionally with myelofibrosis (n=1) 
Schepp et al. (2016) 2/2 Anemia (n=1)   
van Montfrans et al. (2016) 9/9 Lymphopenia and anemia (n=9); thrombocytopenia (n=3)   
Fellmann et al. (2016) 1/2 Neutropenia    
Ben-Ami et al. (2016) 5/5 Anemia (n=5); thrombocytopenia and lymphopenia were additionally described 
Red cell aplasia on BM evaluation 
(n=2) 
Keer et al. (2016) 0/1  -   
Hsu et al. (2016) 1/1 
Patient developed BM failure (neutropenia and 
hypocellular marrow) necessitating BM 
transplantation. 
Lymphohistiocytic aggregates noted 
on marrow analysis. 
Poswar et al. (2016) 0/1  -   
Nanthapisal et al. (2016) 6/15 Lymphopenia (n=6)   
Uettwiller et al. (2016) 2/2 Lymphopenia (n=1); lymphopenia and anemia (n=1)   
Elbracht et al. (2017) 0/1  -   
Hashem et al. (2017) 9/9 
5 patients previously reported. pancytopenia (n=4); 
Pure red cell aplasia (n=6); neutropenia (n=2); 
immune thrombocytopenia (n=1); anemia and 
lymphopenia (n=1) 
Pre-transplant marrow pathology for 
patients not described in report. 
Hashem et al. (2017) 1/1 BM failure (pure red cell aplasia and neutropenia); treated with BM transplantation 
Erythroid hypoplasia, decreased 
granulopoiesis, mild eosinophilia 
and increased T-lymphocytes with 
normal cellularity. 
Omoyinmi et al. (2017) 0/2     
Caorsi et al. (2017) 0/15  -   
Skrabl-Baumgartner et al. (2017) 2/2  Anemia (n=2)   
Schepp et al. (2017) 7/11 
2 patients previously reported. Lymphopenia and 
anemia (n=3); lymphopenia (n=1); lymphopenia 
and thrombocytopenia (n=1); anemia and 
thrombocytopenia (n=1); neutropenia and 
thrombocytopenia (n = 1) 
  
Alsultan et al. (2017) 1/1 Lymphadenopathy; thrombocytopenia    
Lamprecht et al. (2018) 0/1     
Cipe et al. (2018) 1/1 Neutropenia    
Gunthner et al. (2018) 0/1     
Sahin et al. (2018) 4/8 2 patients previously reported; lymphopenia (n=3); pancytopenia (n=1)   
All novel DADA2 patients with 
hematological manifestations 63/147 (42.8%) 
Patients described in more than one publication 
accounted for in prevalence calculation   
 




















































































































































































































































































2.8.5 Telomere biology disorders 
Telomeropathies or telomere biology disorders (TBDs) consist of a range of clinical conditions 
resulting from impaired telomerase function. Telomerases are enzyme complexes specialised for 
the retention of terminal chromosomal DNA sequences, namely telomeres, which are not 
duplicated during the DNA replication process. Telomeres consist of repetitive DNA sequences 
located at each end of the chromosomes that protect the extremities from degradation or 
spontaneous DNA-repair activities. In humans, telomeres consist of tandem repeats of the 
‘TTAGGG’ motive (highly variable in length among different individuals), which is the substrate 
for telomerase activity (Figure 10; Sandin et al. 2014; Bertuch 2016).  
The first inherited disorder described as a TBD was dyskeratosis congenita (DKC). DKC is a 
severe multisystem disease presenting with cytopenia of one or more haematopoietic cell lineages 
with the clinical hallmarks of reticulate skin pigmentation, nail dystrophy and oral leucoplakia 
(Heiss et al. 1998). The most serious clinical feature in DKC is bone marrow failure, which is 
detected in the majority of patients and determines premature mortality. Furthermore, DKC 
patients display a heightened risk for malignancies, fatal pulmonary complications and 
immunodeficiency (Bertuch 2016). Currently, DKC is associated with alterations in 11 genes: 
DKC1 (causing X-linked recessive inheritance), TERT, TERC, NHP2, NOP10, ACD, WRAP53, 
TINF2, RTEL1, CTC1 and PARN. All these genes except DKC1 are associated with autosomal 
recessive and/or dominant inheritance (Dokal 2000; Vulliamy et al. 2006; Ballew et al. 2013; 
Townsley et al. 2014; Bertuch 2016). According to recent classifications, the term ‘DKC’ is mostly 
used to classify well-defined childhood symptoms (Townsley et al. 2014). Based on clinical signs, 
a rare, severe phenotypic variant of DKC is defined as Hoyeraal-Hreidarsson syndrome (HHS). 
HHS leads to immunodeficiency, cerebral hypoplasia and intra-uterine growth retardation in 
addition to bone marrow failure (Dokal 2000; Glousker 2005).  
From a biological perspective, the premature senescence of stem cells causes telomere 
shortening, which is markedly evident in the highly proliferating mucocutaneous tissues (Bertuch 
2016). In the absence or delayed onset of pathognomonic mucocutaneous findings, the diagnosis 
of DKC has often been overlooked (Lim et al. 2014). Molecular diagnostic approaches based on 
NGS could improve the detection rate of TBDs, which is difficult due to the wide spectrum of 
clinical presentations and the lack of a conclusive laboratory test. The value of a prompt diagnosis 








Figure 11. Structure of human telomeres and telomerase recruitment. Adapted from Sandin and Rhodes (2014). 
Telomeres consist of repeats of the ‘TTAGGG’ motive, extending from the telomeric extremity to constitute a long double-stranded DNA region 
ending with a single-stranded G-rich overhang. In addition to histone-mediated packaging, telomeric DNA is organised into a shelterin capping 
structure by the binds with sequence-specific DNA binding proteins (TRF1, TRF2, Rap1, TIN2, TPP1, and POT1). TRF1 and TRF2 bind to specific 
double-stranded telomeric DNA sequences, and TIN2 allows for the formation of bridges with TRF1 and TRF2 and TPP1. The TPP1/POT1 complex 
is located on the G-overhang through the binding of POT1 with a single-stranded G-overhang. The telomerase complex TERT/TER begins its 
activity from the end of the telomeres. The recruitment requires an interaction between TPP1 and TERT (N-terminal domain) and specific sequence 
matching between the G-overhang and the template region of TER (telomerase RNA subunit). 
 
2.9 Population structures of Finns and the Finnish disease heritage 
Currently, the availability of a large-scale variation dataset allows for the characterisation of the 
genetic features of different populations and the link with clinical phenotypes. Demography can 
shape the genetic structure of populations and can result in different variation loads among 
individuals. A specific example is provided by the proportional increase of detrimental alleles in 
European American individuals compared to African Americans due to the so-called ‘Out-of-
Africa bottleneck’ (Lohmueller et al. 2008). Conversely, other studies depicted similar loads of 
deleterious alleles in Europeans and West Africans, suggesting that demographic factors are 
unlikely to affect the proportions of deleterious variants in human populations or the average 
burden of mutations in individuals (Simons et al. 2014).  
The actual Finnish population has been considered to likely be derived from small founder 
groups settling in the country after the glacial course. Consequently, the population history of 
Finland includes a restricted number of founders, isolation, several population bottlenecks and 
recent expansions (Peltonen et al. 1999). A comparison to non-Finnish Europeans showed a 
proportional enrichment of rare deleterious variants in Finns, notwithstanding the notably low rate 
of overall variations in the population. As assumed, the distribution of common alleles (non-
synonymous or synonymous) appears to be unvaried. Instead, the frequency of rare detrimental 
variants has increased due to the founding bottleneck processes, and there was possibly not enough 
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time for the negative selection to reduce the load. The increased load of rare deleterious variants 
may also have resulted due to aspects of the Finnish population’s shaping processes other than 
bottleneck processes (Lim et al. 2014).  
The noticeable enrichment of some deleterious variants and the loss of others resulted in a 
phenomenon called the Finnish Disease Heritage (FDH). According to the definition, FDH 
disorders are more frequent in Finland than in  
any other country (if present). For each FDH disorder, a causative founder mutation (Finmajor) 
accounts for the majority, if not the total, of affected individuals, with an allelic frequency higher 
in Finland than elsewhere (Peltonen et al. 1999; Norio 2003). At present, a total of 36 disorders is 
included in the FDH with reported mutations in 40 genes (Polvi et al. 2013; Kääriäinen et al. 2017) 
(Figure 11). The overall impact of FDH must not go underestimated due to the low prevalence of 
the individual disorders (from 1:8000 to 1:100.000 in Finland). FDH syndromes present a wide 
spectrum of associated phenotypes. Estimates report one-third of the conditions associated with 
(mild to severe) intellectual disabilities, one third with vision defects and one-half causing 
premature death (Norio 2003). In addition to the peculiar population architecture, genetic research 
in Finland revealed the possibility to access detailed genealogical records and longitudinal national 
health registers, allowing for the development of personalised risk evaluation strategies in 











3 AIMS OF THE STUDY 
 
The purpose of this thesis study was to shed light on the genetic bases of PIDs in the Finnish 
population and to implement NGS-based methods for routine diagnostic testing.  
 
Part of the study subjects had previously been ruled out for alterations of established candidate 
disease-genes. Moreover, the varied clinical manifestations within the cohort and the overlap of 
symptoms among different syndromes would have prompted the possibility of pathogenic 
variations in a large number of causal-genes. Considering these hurdles, we targeted all the known 
protein-coding genes, without setting clinical-based assumptions or restrictions. This, namely 
hypothesis-free, WES-based approach was applied to identify PID-causing variants and to provide 
prompt genotype-phenotype correlations for heterogeneous syndromes. 
 
In detail, the goals of the project were: 
 
1. To identify disease-causing genetic variants in Finnish patients with unexplained immune and 
haematological diseases using hypothesis-free WES-based methods. 
 
2. To characterise the phenotypic spectrum of rare PID entities providing insights on the biological 
function of the involved genes. 
  
3. To improve routine PIDs genetic diagnostics at the single patient-level, especially for highly 
heterogeneous and/or atypical clinical presentations.  
  
4. To evaluate the effects of the genetic background of the Finnish population on the distribution 




















4 MATERIALS AND METHODS 
 
4.1 Study subjects  
All the genetic analyses performed in this study were intrinsic to clinical setting for a set of 212 
Finnish individuals with a clinical suspicion of PIDs. The study subjects did not present 
consanguineous origins and displayed a broad spectrum of immunological and/or haematological 
phenotypes suggestive of monogenic disorders. Inclusion in the study was based on clinical 
diagnosis and/or laboratory findings performed at the University Hospitals of Finland (Helsinki, 
Kuopio, Oulu, and Tampere). 
4.1.1 Ethical issues (I, II, III) 
The studies were undertaken in observance of the principles of the Helsinki Declaration with the 
approval of the ethics committees of Helsinki and Oulu University Hospitals, Finland. All 
participants provided written informed consent preceding the sample collection. For the children 
enrolled in the study, written informed consent was provided by one of the parents. 
 
4.2 Generation and analysis of genetic data 
 
4.2.1 Whole-exome sequencing (I, II, III) 
The WES was performed for all studied patients at the FIMM sequencing centre (the Institute for 
Molecular Medicine Finland, FIMM; Helsinki, Finland) with the exception of P1.1 (study III), 
who was tested at the Laboratory of Human Genetics of Infectious Diseases, Necker Branch, 
(Necker Hospital for Sick Children, Paris, France). In brief, genomic DNA and RNA were isolated 
from peripheral blood by standard methods. The SureSelect Clinical Research Capture Exome 
(Agilent, Santa Clara, CA, USA) and Nextera®Rapid Capture Exome (Illumina, San Diego, CA, 
USA) kits were used for target enrichment. Paired-end sequencing was carried out on the HiSeq 
1500 or HiSeq 2000 platform (Illumina, San Diego, CA, USA). An in-house pipeline (VCP) was 
used for the analysis of the generated WES data (Sulonen et al. 2011). 
 
4.2.2 Sequence read processing (I, II, III) 
Initially, raw Illumina reads were merged (SeqPrep 0.4.5). The ends of the paired reads underwent 
trimming with all the resulting reads removed if shorter than 36 bases. The remaining paired and 
single reads were aligned separately against the human reference genome hg19 (GRCh37, ensembl 
version 70) using the Burrows Wheeler Aligner (0.5.10). The alignment of indels was enhanced 
by GATK Indel Realignment (1,5-3) (McKenna et al. 2010, DePristo et al. 2011, Van der Auwera 
et al. 2013). The results of the alignment were refined by the removal of potential PCR-related 
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biases (i.e. duplicates) (Picard MarkDuplicates, 1.65) and read pair mapping to multiple genomic 
targets (with one or both reads). 
4.2.3 Single-nucleotide and indel variant calling (I, II, III) 
The variant calling processes were carried out using SAMtools mpileup (0.1.18) and dindel (1.01). 
The minimum depth set for SNP calling was seven reads. Any call with a coverage ratio between 
reference (R) and variant (V) calls: (R / (R + V)) smaller than 0,2 was assumed to be homozygous, 
and the remainder was considered heterozygous. Quality filtering was applied to the called SNPs, 
discarding those with a ratio between the sum of the quality values of reference (R) and the variant 
(V) calls: R / (R + V) higher than 0,8. For two different variant calls and no reference for a given 
position, the highest in terms of the quality call was used as a reference. 
4.2.4 Variant and gene annotation (I, II, III) 
The Annovar toolkit was used to annotate and to predict the functional consequences of the 
identified variants (Wang et al. 2010, Chang et al. 2012).  
The allelic frequencies in the general population were retrieved using the following databases: 
the national SISu project (http://sisu.fimm.fi/), the Exome Aggregation Consortium (ExAC, 
accessed in July 2015) (Lim et al. 2014) and the Genome Aggregation Database (gnomAD) 
(Cambridge, MA, USA; http://exac.broadinstitute.org; accessed in July 2015) (Lek et al. 2016).  
The annotations of genes or variants to human phenotypes were based on the Online Mendelian 
Inheritance in Man, OMIM® database (https://omim.org/) (Hamosh et al. 2005), the NCBI 
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), the Human Gene Mutation Database 
(HGMD®) (Krawczak and Cooper, 1997), the LOVD database 
(http://databases.lovd.nl/shared/genes/) and the literature investigation. 
4.2.5 Variant filtering and analysis (I, II, III) 
To reduce the list of variants for the analysis, all common (frequencies above 0,01 in the general 
population) and non-coding variants were discarded. Filtering was based on allelic frequency data 
from gnomAD and SISu. Furthermore, all variants that exceeded the frequency of 0,05 (data from 
an in-house database) were rejected.  
All rare variants located in the coding regions were prioritised based on the predicted transcript 
level consequences. Frameshift, nonsense, splicing and missense variants were included. For 
missense variants, the predicted effect on the protein level was estimated in silico by CADD 
(Kircher et al. 2014), PolyPhen-2 (Adzhubei et al. 2010), SIFT (Kumar et al. 2009) and Mutation 
Taster (Schwarz et al. 2014). 
For multi-case families or a suspicion of family history for a specific disease, the phenotypic 
segregation pattern was taken into account during the filtering process.   
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4.2.6 Variant pathogenicity estimation (I, II, III) 
All filtered variants were prioritised based on in silico prediction tools (prediction of the effect on 
the protein and the conservation of the affected amino acids) and underwent evaluation according 
to the ACMG Standards and Guidelines (Richards et al. 2015). Only variants classified as 
pathogenic, likely pathogenic or associated with an unknown significance were considered to have 
potential clinical relevance. 
4.2.7 Variant confirmation and segregation analysis (I, II, III) 
The confirmation of all the identified variants and the screening of family members (when 
available) were performed by PCR amplification on genomic DNA followed by Sanger 
sequencing. The sequencing was performed using the BigDye Terminator Cycle Sequencing kit 
and capillary electrophoresis executed on an ABI-3730XL DNA Analyser (Applied Biosystem, 
Foster City, CA, USA). The resulting electropherograms were analysed using Sequencer 5.1 (Gene 
Codes Corporation, Ann Arbor, MI USA). Some of the identified causal variants were tested at 
the transcript level by Sanger sequencing of cDNA obtained from RNA using the SuperScript® 
VILO cDNA Synthesis kit (Life Technologies, Carlsbad, CA). The kit was used according to 
the manufacturer’s instructions (0,5-2μg of RNA, 20μl of total reaction volume).  
4.2.8 Exclusion of germline mutations in the GATA2 gene (II) 
The hypothesis of GATA2 haploinsufficiency in patients P1 and P2 (study II) was tested by Sanger 
sequencing of cDNA (as described above). In brief, heterozygous SNVs (previously detected by 
WES) in the coding region of GATA2 (Ensembl ENSG00000168610, ENST00000588969; 
GRCh37.p13) were targeted to compare zygosity at the transcript level. The presence of only one 
allele in the cDNA was considered to potentially reveal haploinsufficiency. Because P1 did not 
carry any heterozygous coding variant in GATA2, all reported haploinsufficiency-causing variants 
(coding or not) were investigated according to the Human Gene Mutation Database. 
4.2.9 Exclusion of somatic mutations in the STAT3 gene (II) 
Somatic STAT3 (Ensembl ENSG00000179348, ENST00000341105; GRCh37.p13) variants were 
screened by deep-amplicon sequencing in patients P1-4 and P6-7 (II) and in two healthy controls. 
The targeted sequencing of the exons 19, 20 and 21 (corresponding to the functional Src 
Homologue 2 [SH2] domain) was performed using the Illumina Miseq platform (Illumina). 
4.3 Functional studies of the identified variants  
4.3.1 DADA2 measurement (II) 
Plasma ADA2 activity levels were measured in seven individuals. For patients P1, P2, P6 and P7, 
the measurement was performed on EDTA-treated plasma (expressed as mU/mL; reference values: 
12,8mU/mL, SD 2,6 (min-max) in adults (>18years old), 27mU/mL, SD 2,3 (min-max) in children 
(<18y)) (Zhou et al. 2014). In the remaining patients (F2.3, P4.1 and P4.2), DADA2 activity levels 
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were assessed on filter paper (activity measured in mU/g of protein, reference values: 132,3mU/g, 
SD 51.1). The previously mentioned method was partially modified to be executed on filter paper 
(Ben-Ami et al. 2016). Two of the patients were not tested (P3 underwent an allogenic stem cell 
transplant in September 2016; P5 was deceased in 1990).  
4.3.2 Telomere length analysis (III) 
The relative telomere length (RTL) was determined in the studied patients using a quantitative 
PCR-based method described by Cawthon (2002). Minor modifications were applied to the 
described protocol. Briefly, the samples consisting of 17,5ng of DNA (from peripheral blood 
leukocytes) were analysed for separate telomere (TEL) and single copy gene (HBG) reactions 
using the ABI 7900HT platform (Applied Biosystems). Each sample was analysed in triplicate 
wells in 96-well PCR plates on two separate occasions. Cell-line DNA (CCRF-CEM) and control 
samples were included in all runs to monitor PCR efficiency and to derive a standard curve. The 
TEL/HBG (T/S) values were derived using the 2−ΔCt method (ΔCt = CtTEL-CtHBG). The RTL 
values were obtained by dividing the samples’ T/S values by the T/S value of a reference DNA. 
The RTL values of the patients were compared to normal controls (n=113; age=0-83 years).  
4.3.3 T-cell sorting and clonality analysis (II) 
Peripheral blood mononuclear cells from two patients with LGL lymphoproliferation (P1, P2) were 
sorted into CD8+ and either CD8- or CD4+ populations by flow cytometry (BD Biosciences 
Multitest, CD45, CD3, CD8 and CD4 antibodies). A fraction of the isolated cells was used to check 
the purity of the sortings (FACS Aria, Beckman-Coulter Immunotech). Potential clonal expansions 
were tested by a quantitative determination of the TCR Vβ repertoire of human T lymphocytes, 
which was performed using flow cytometry. The assay was executed on peripheral blood samples 
using the IO Test® Beta Mark TCR Vβ Repertoire Kit (PN IM3497, Beckman Coulter 
Immunotech). In brief, the kit consists of eight vials with mixtures of 24 different conjugated TCR 
Vβ antibodies encompassing approximately 70% of the normal human TCR Vβ repertoire. The 
manufacturer established normal means (with minimum and maximum values) derived from 85 
normal blood specimens (the tubes detecting Vβ4, Vβ7,2 and Vβ13,2 have been tested on a 
different cohort of 46 normal specimens). Subsequently, the samples were stained with CD3, CD4 
and CD8 antibodies (BD Biosciences) to further characterise the possible clonal expansions. 
4.4 Analysis of the distribution of PID-causing variants  
4.4.1 Enrichment analysis (I, II) 
Publicly available data (ExAC and gnomAD) were used for the comparison of the frequency of 
PID-causing variants in different populations. The allelic distributions in Finns and individuals 
with European and non-European ancestries were compared using Pearson’s chi-squared test (108 
simulations, statistical significance p<0,05). All the data were retrieved and analysed using in-
house designed IT procedures.  
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4.4.2 Population study (I) 
The estimation of haplotype blocks potentially including the AICDA p.(Met139Thr) (c.416T>C; 
rs200858797) variant was performed on data from the SISu cohort (3316 unaffected, 11 
p.(Met139Thr) carriers) using PLINK (1,07, http://pngu.mgh.harvard.edu/purcell/plink/; Purcell 
et al. 2007) and Haploview (Barrett et al. 2005).  
Sixty-one common markers selected in a 2Mb window around the target variant (Minor allele 
Frequency-MAF > 5%, genotyping rate threshold >95%, not failing Hardy Weinberg equilibrium 
test) were used. The following options were applied: ‘--maf 0,05 --geno 0,05 --hwe 1e-5 --block -
-hap-freq’ (PLINK) and ‘solid spine of LD option’ (Haploview).  
The results were replicated using the same analytical protocol and options on a different cohort 
(6735 healthy individuals, 20 p.(Met139Thr) carriers) of three Finnish clinical and epidemiological 
sample collections (the Finnish Twin Cohort study, the National FINRISK Study and the Migraine 
Family Study). The samples were genotyped with Infinium HumanCoreExome-24 BeadChips 
(Illumina). For the segregation analysis, 113 common markers (MAF > 5%) in a 2Mb window 
surrounding the p.(Met139Thr) were selected.  
According to the detected haplotype structure, a potential ancestral Finnish haplotype 
including the studied AICDA variant was monitored. Therefore, the data from the two different 
datasets defining the 1,1Mb region surrounding the p.(Met139Thr) were defined. The genotypes 
of the enclosed 80 markers were extracted in all the carriers (n=31) from the different datasets. In 
detail, the genotypes of 34 markers were available in the SISu cohort, 51 were available in the 
other collections and only five markers were genotyped in both datasets.  
A cryptic relatedness analysis was also performed on the samples from the Finnish Twin 
Cohort study, the National FINRISK Study and the Migraine Family Study cohorts. The overall 
IBD sharing was compared among the p.(Met139Thr) carriers (n=20) and the remainder of the 
individuals using 132.250 genome-wide markers (MAF >5%, genotyping rate threshold > 95%, 
not failing Hardy Weinberg equilibrium test) in apparently unrelated individuals (piHat<0.05, 
r2>0,5). To estimate the individual genome-wide identity by descent (IBD), the following PLINK 
options were applied: ‘--genome --maf 0,05 --geno 0,05 --hwe 1e-5 --min 0,01’. The average 
values of the ‘observed IBD sharing’ (piHat) were compared in carriers and non-carriers using a 
Welch’s two-sample t-test (108 simulations).  
4.4.3 Geographic distribution analysis (I) 
The geographic distribution of the AICDA p.(Met139Thr) alleles in Finland was studied by 
tracking the familial HIGM2 samples and by using data from the SISu consortium, the Finnish 
Twin Cohort study, the National FINRISK Study and the Migraine Family Study. Overall, 
information was retrieved about the place of birth for 27 of the 32 known p.(Met139Thr) carriers. 
Fifteen of the carriers originated from Eastern Finland (Kuopio, Viipuri), five from Northern-
Ostrobothnia, four from Northern Finland (Ranua) and three from the Helsinki area (currently 
representing a mixed population).  
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5 RESULTS AND DISCUSSION 
 
5.1 Overview of the study patients  
The subjects included in the presented studies underwent clinical WES due to a suspicion of 
immune and/or haematological inherited diseases. All 212 study subjects were Finnish and mostly 




Figure 13. Categorisation of the clinical phenotypes of the patients in the studied dataset (n=212). 
The categories were defined according to the 2017 Primary Immunodeficiency Disease Committee Report (Picard et al. 2018). 
 
5.2 Identification of a disease-causing founder mutation in a population 
isolate (I) 
5.2.1 Screening of AICDA mutations in Finnish patients with hyper-IgM 
syndrome type 2 (HIGM2)  
The original index case displayed undetectable levels of switched memory B cells and other 
clinical features suggestive of familial HIGM2 because the other two family members presented 
similarly. All the affected members of the family (n=3) were remitted to WES, with an 
identification in all the patients of a bi-allelic HIGM2-causing mutation (p.(Met139Thr)), 
PMID:16964591) in the AIDCA gene (Ensembl ENSG00000111732, ENST00000229335, 
GRCh37.p13). In the case of a deceased familial patient (PI-I), targeted Sanger sequencing 
conducted on an archived sample retrieved the same genotype. The screening revealed two healthy 
relatives carrying one copy of the variant.  
Following the identification of the disease-causing variant by WES, the patient cohorts of the 
paediatric and adult immunodeficiency units of all five Finnish university hospitals was screened 
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for phenotypes compatible with either AID or UNG deficiency. Patients with a) low or absent IgA, 
IgG and IgE levels but normal or high IgM levels according to the laboratory reference values 
along with b) missing smB cells but normal or high levels of MZB in B cell phenotyping (for 
methods, see Haapaniemi et al. 2015) were included in the screening. All the additional Finnish 
patients (n=4) were screened, and homozygotes were identified for the p.(Met139Thr) mutation. 
 
5.2.2 Enrichment of AID-causing variant in the Finnish population 
The HIGM2-causing p.(Met139Thr) mutation was found with an allelic frequency of 0,012% in 
the 57.391 exomes of the ExAC. The mutation is rarer in other population subsets included in the 
ExAC (allelic frequency of 0,0047% in non-Finnish individuals with European ancestry 
(n=31.686) and an absence of carriers in other populations of non-European ancestries 
(n=22.692)).  
Comparing the different subgroups of European descent, the p.(Met139Thr) mutation emerged 
as largely enriched in Finland (38,56-fold allelic frequency, p <0,001) with 11 uniallelic carriers 
of 3013 exomes (MAF 0,18%). The same level of enrichment was confirmed using the gnomAD 
dataset. The analysis of the allelic frequency of other AICDA variants did not show statistically 
significant differences between different populations. Interestingly, no other deleterious AICDA 
mutations have been previously identified in Finnish AID deficiency patients, suggesting the 
p.(Met139Thr) is its causal factor in Finland. Thus, according to the p.(Met139Thr) allelic 
frequency, the theoretical prevalence of HIGM2 patients among Finns should be in the range of 
0,81/106 individuals. 
5.2.2.1 Analysis of the geographic distribution of the founder allele  
To study the geographical distribution of the enriched AICDA p.(Met139Thr) in Finland, 
information on the birthplace of the studied individuals and of all the carriers (27 out of 31) 
included in the SiSu dataset and in other Finnish sample collections was obtained.  
All the HIGM2 patients and almost all the carriers (24/27) originated from Eastern and 
northeastern Finland. These regions namely correspond to the late settlement areas of the Finnish 
population, implying a single origin of the p.(Met139Thr) alleles that all of the patients carried 
(Figure 14). Three of the carriers were born in the Helsinki area, which during the last centuries 
has been characterised by a considerable immigration from the rest of Finland. 
5.2.2.2 Identification of the founder mutation in the AICDA gene  
To decipher the possible link between the enrichment of the p.(Met139Thr) and the genetic 
background of Finns, haplotypes shared by the carriers were identified using data from the SiSu 
cohort (3325 WES of Finns inclusive of 11 carriers.) Initially, the potential haplotype structure of  
a 2Mb genomic region around the p.(Met139Thr) was determined. Two haplotype blocks were 
noted 90 kb upstream and 51kb downstream of the variant, respectively. From a genomic 
perspective, a ‘recombination hotspot’ was observed spanning 10kb and enclosing the AICDA gene 
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(UCSC Genome Browser, Kent et al. 2002). It was speculated that the presence of a 
‘recombination hotspot’ could have potentially reduced the conservation of the ancestral allele as 
well as the possibility to track it. Therefore, to increase the detection power, the genetic data 
retrieved for all the p.(Met139Thr) carriers present in the two different datasets were combined. 
The WES data from the SiSu cohort and the two familial carriers (exome sequenced as part of the 
clinical workout) and the genotyping data from 29 individuals of the Finnish epidemiological and 
clinical cohorts were also combined. Overall, for the 31 carriers, the different possible allelic 
combinations for each of the retrieved haplotype blocks were compared. A 207,5kb core haplotype 
inclusive of the p.(Met139Thr) variant present in all the carriers (Figure 15) was identified. The 
subsequent comparison of the genomic identity (measured as pairwise genome-wide IBD) showed 
a significant higher relatedness within the p.(Met139Thr) carriers (average piHat=0,007±0,0027) 
than in the general population (piHat=0,003±0,005)) (p=1,59e-12). Although the structure of a 
potential founder haplotype was disrupted due to a recombination hotspot, the genomic identity 
and the haplotypes shared among the carriers were consistent with the single origin of the 






Figure 14. Distribution of the AICDA p.(Met139Thr) carriers in Finland. 
Blue triangles point to the geographical origins of the Finnish carriers (n=27) of the p.(Met139Thr) variant included in the SISu and in the 
epidemiological and clinical Finnish sample collections (the Finnish Twin Cohort study, the National Finrisk Study and the Migraine Family 
Study). Yellow symbols indicate the birthplaces of carriers’ parents if discordant. The birthplaces of the patients are indicated by a purple spot, 
listing the number of the Family (from I to IV). For Families III and IV, the mother corresponds to ‘a’ and the father to ‘b’. The black dots mark 


































































































































































































































































































































































































































































































































































































































































5.3 Identification of novel phenotypic traits in patients with adenosine 
deaminase 2 deficiency (II) 
 
5.3.1 Identification of ADA2 mutations in Finnish patients with adenosine 
deaminase 2 deficiency (DADA2) 
The sequencing of patients with a clinical suspicion of PIDs identified seven individuals with 
biallelic variants in the ADA2 gene (Ensembl ENSG00000093072, ENST00000399837, 
GRCh37.p13). Part of the studied subjects presented with cytopenia (P1-P4.1), and others 
belonged to a multi-case family with cutaneous Polyarteritis nodosa (cPAN) and central nervous 
system complications (P5-P7) (Table 4). All the patients had non-consanguineous origins and 
carried the p.Arg169Gln mutation (PMID 24552285): in three cases, homozygotes (P1-P3), and in 
four cases, a compound heterozygote with pathogenic variants (the novel p.(Leu311Arg) in P4.1 
and the c.973-2A>G (P5-P7). The p.(Leu311Arg) variant was defined as pathogenic according to 
the ACMG criteria,  the c.973-2A>G  according to the ClinVar  database (ID541735). The analysis 
was extended to the patients’ relatives by targeted screening, identifying two other patients (F2-3, 
sister of P2 and P4.2; aunt of P4.1). 
 
5.3.1.1 Functional studies confirming DADA2 
In seven patients, deficient levels of ADA2 protein activity (in the plasma) were functionally 
assessed. Patient P3 was not included in the testing because an allogeneic stem cell transplant was 
performed (September 2016). P5 had previously deceased (1990). 
 
5.3.1.2 Enrichment of rare DADA2-causing variants in the Finnish population   
The p.Arg169Gln has a frequency of 0,05% in the gnomAD dataset (of 138.611 genome-sequence
d samples). The allelic frequency in Finns was 0,2% (52 carriers of 12.896 individuals), which is h
igher than in the general population. Compared with the group of non-Finnish European individua
ls (0,06% in 63.354 individuals), the p.Arg169Gln resulted in 3,32-fold enrichment in Finns (p <1
e-8). The p.(Leu311Arg) variant has a frequency of 0,005685% in the gnomAD dataset and 0,049
% in Finns. The mutation resulted in a significant enrichment in Finns in comparison with other g
roups of European descent (18,36-fold, p=5,5e-7). The c.973-2A>G variant displayed a MAF of 0,
012% without significant differences among the population groups. 
 
5.3.2 Characterisation of the Finnish patients with atypical phenotypes 
The initially studied four patients (P1-P4.1) displayed variable degrees of cytopenia, and for three 
of them (P1-P3), signs of lymphoproliferation were described (Table 4). Interestingly, they did not  
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present any of the autoimmune vascular or haemorrhagic complications typical of DADA2. A 
clinical evaluation of the patients’ relatives indicated potential lymphoproliferation symptoms in 
two patients (F2-3, P4.2). F2-3 was an asymptomatic sister of P2 presenting with mild cytopenia. 
P4.2 was an aunt of P4.1, originally diagnosed with CVID. 
The absence of the canonical DADA2 phenotypes along with the recurrence of haematological 
manifestations creates additional options for the clinical management of the patients. The varied 
haematological (mostly cytopenia) and lymphoproliferative symptoms manifesting in several 
DADA2 patients might require targeted therapeutic options. After DADA2 is ascertained, the 
clinical strategies should be developed in consideration of the possibility of autoimmune or 
haemorrhagic manifestations even in absence of PAN or other vasculitic phenotypes. 
 
5.3.2.1 Lymphoproliferative phenotype resembling T cell large granular 
lymphocyte leukaemia 
Of the three patients with lymphoproliferation (P1-P3), two (P1, P2) exhibited a CD3+CD8+ T 
cell large granular lymphocytic (T-LGL) infiltration of the bone marrow. Autoimmune findings 
suggestive of T-LGL were first reported in P1 at the age of 8y and confirmed at 17y. For P2, the 
diagnosis of T-LGL was performed at 31y. P3 already showed lymphadenopathy and T-cell 
hyperplasia in the bone marrow at the age of 4y. P4.1 was only 5y at the time of the last clinical 
evaluation; therefore, given the variable onset of lymphoproliferation, the possibility of developing 
it later in life cannot be ruled out. F2.3 was initially reported to have mild cytopenia, but a further 
detailed immunological evaluation (age of 46) showed a marginal T-LGL clone in the peripheral 
blood (0,06x10-6/l), although it did not fulfil the standard criteria for a diagnosis of T-LGL 
leukaemia. P4.2 was initially diagnosed with CVID, but supplementary examinations at the age of 
18 revealed mild signs of lymphoproliferation. Altogether, these findings indicate the occurrence 
of early-onset T-cell clonal expansion in patients with DADA2, though the causal link is still 
unclear.  
5.3.2.2 T-cell clonality analysis  
A T-cell clonality analysis was performed in the two patients with LGL lymphoproliferation (P1, 
P2). Through flow cytometry, peripheral blood mononuclear cells were sorted into CD8+ and 
either CD8- or CD4+ populations. The screening showed clonal expansions of the CD8+ fraction 









































































































































































































































































































































































































































































































































































5.3.2.3 Exclusion of germline GATA2 variants in patients with T-LGL  
The clinical phenotype of P1 and P2 partly overlapped with features of GATA2 deficiency or with 
the phenotypes previously observed in patients carrying activating STAT3 mutations (reported 
autoimmunity, hypogammaglobulinemia and lymphoproliferation). Therefore, the possibility of 
germline variants in both genes and haploinsufficiency of GATA2 were excluded. The occurrence 
of GATA2 haploinsufficiency was ruled out in P2 by Sanger sequencing on cDNA of heterozygous 
coding region variants retrieved by WES. The sequencing showed that both alleles were expressed. 
Since P1 did not carry any heterozygous variant in the coding region, only the presence on cDNA 
of the coding and intronic variants reported as haploinsufficiency-causing in the Human Gene 
Mutation Database (HGMD, https://portal.biobase-international.com/hgmd/) could be excluded. 
5.3.2.4 Screening of somatic variants in the functional domain of STAT3 
The high-coverage targeted sequencing of exons 19, 20 and 21 of STAT3 was performed in all six 
living patients (P1-P4.1, P6-P7), and four variants were identified in P1 and P2, which were 
patients with T-LGL. The retrieved variants in the sorted CD8+ T- and CD8- T- cell fractions (P1) 
or in the CD4+ T-helper cell fraction (P2) were screened. P1 carried two variants (p.(Asn647Ile), 
p.(Asp661Val)) in ~2% of cells in the CD8-negative fraction. The two variants were also observed 
in CD8+ cells with a much lower MAF. The p.Asn647Ile was present in P2 as well (CD4+ and 
CD8+ fractions) in addition to the p.(Ser614Arg) variant identified with a very low frequency 
within the CD8+ subset. The identified variants exhibited a very low frequency and were shared 
by several small CD8 cell clones. In addition, they were not represented in the major T-LGL clones 
(data not shown). This evidence led to the speculation that the identified somatic STAT3 variants 
do not likely provide a major contribution to the described lymphoproliferative phenotype. 
5.3.3 Characterisation of Finnish patients with the canonical DADA2 
phenotype 
Multiple members of a multi-case family originating from Eastern Finland (P5-P7) were diagnosed 
with cutaneous PAN with central nervous system complications. The described phenotypes 
matched the canonical clinical features originally associated with DADA2 (Zhou et al. 2014, Elkan  
et al. 2014). Of interest, a 40-year-long follow-up documented that all the vascular flares 
experienced by patients occurred in a short time span after carefully reported bacterial infections, 
regardless of the treatments applied. The infections mostly involved the respiratory tract or the 
teeth. The possible correlation between bacterial infections and the occurrence of vascular flares 
might be of interest for the clinical management of patients with the ‘classic’ vasculitic DADA2 
phenotype. Clinical evaluations excluded the occurrence of lymphoproliferation in P6 and P7 up 
to their late 30s. P5-P7 carried two different heterozygous ADA2 variants: the aforementioned 
p.Arg169Gln and a novel donor-splice variant (c.973-2A>G). The mutation screening of the 
transcripts of ADA2 in the living patients (P6, P7) revealed nonsense-mediated decay (NMD) 
prompted by a premature stop codon after the c.973-2A>G variant. Therefore, the ensuing mono-
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allelic expression of p.Arg169Gln might resemble its homozygousity observed in the previous four 
patients with lymphoproliferative phenotypes (P1-3, P4.2). This might suggest the possibility of 
the lack of one ADA2 allele or of other genetic and/or environmental factors to modify the 
phenotype.   
 
5.4 NGS-based diagnostics of genetically and clinically heterogeneous 
telomere biology disorders (III) 
 
5.4.1 Analysis of NGS data revealed mutations in genes associated with 
telomere biology disorders (TBD) 
In this study, using ‘hypothesis-free’ WES we have identified disease-causing variants in four 
patients presenting with varied immunological and/or haematological phenotypes (Table 5). In 
four patients were detected causal variants in genes associated with telomere biology disorders 
(TBDs), providing genotype-phenotype correlations for heterogeneous syndromes. 
 
5.4.1.1 Identification of TBD-causing variants in patients with different 
phenotypes  
All the studied patients who originated from non-consanguineous Finnish families were remitted 
to clinical WES to obtain a molecular diagnosis. 
Patient 1 (P1.1) was a 24-year-old male presenting with chronic mucocutaneous candidiasis. 
The sequencing revealed a novel variant in the DKC1 gene: c.1218_1219insCAG, 
p.(Asp406_Ser407insGln) (Ensembl ENSG00000130826, ENST00000369550, GRCh37.p13). 
The patient had been diagnosed in early childhood with vesicoureteral reflux and urinary tract 
infections, but no severe infections were ever documented. Since an early age, the fingernails were 
abnormal and easy to break, and he was subsequently diagnosed with poikiloderma (reddish skin 
in the neck and upper thorax). After the age of 10-13 years, recurrent aphthous ulcers on the oral  
mucosa and leucoplakia (dorsal and ventral sides of the tongue) were reported.  Biopsies of 
epithelial tissues supported a diagnosis of leucoplakia and candidiasis, requiring a further 
immunological workup showing only a slight decrease in IgG2 concentration and CD4+ T cells. 
The extension of the analysis to relatives showed similar symptoms in an older brother (P1.2), 
presenting with lightly milder skin, abnormalities of nails and oral mucous membranes and 
recurrent genital candida infections. Research of the familial DKC1 mutation revealed P1.2 as a 
carrier. Due to the inferred X-linked recessive inheritance, clinical information about the maternal 
grandfather (died traumatically in his 40s), who was reported to have nail and skin phenotypes as 
well, was revisited.  
Patient 2 (P2) was an 11-year-old female carrying two heterozygous variants in TERT: 
c.2051A>G, p.(Asp684Gly) (PMID:29483670) and c.3202G>A, p.Glu1068Lys 
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(PMID:28192371) (Ensembl ENSG00000164362, ENST00000310581, GRCh37.p13). The 
segregation analysis showed the two variants were compound heterozygotes, confirming the 
autosomal recessive segregation pattern of the phenotype. The patient was born at term, although 
she was small for gestational age. She experienced normal growth stages by the age of two. 
Developmental delay was not recorded during infancy or later. After the age of four, disorders in 
swallowing and oesophageal strictures were diagnosed, necessitating dilatation interventions. At 
the same time, mild thrombocytopenia and macrocytosis were observed in the peripheral blood; 
nonetheless, the bone marrow showed normal hematopoietic functions. A re-evaluation of the bone 
marrow was performed at the age of 10 years because cytopenia persisted, displaying features 
compatible with a diagnosis of myelodysplasia and hypoplastic anaemia with the exclusion of 
paroxysmal nocturnal haemoglobinuria and Fanconi anaemia. The extensive immunological 
evaluation did not detect any feature of immunodeficiency. No pulmonary, nail or skin symptoms 
were reported except the description of fair and thin hair. P2’s older sister (16 years old) did not 
show any relevant symptoms, and the other close relatives were never diagnosed with cancer or 
had reported DKC features.  
Patient 3 (P3) was a 2-year-old boy presenting with severe immunodeficiency and 
opportunistic infections. Two novel compound heterozygous variants in RTEL1 (Ensembl 
ENSG00000258366; ENST00000318100, GRCh37.p13)) were detected (c.1721G>C, 
p.Arg574Pro, confirmed at RNA transcript level, and c.3724_3725delTG, p.(Cys1242Cysfs*18). 
The segregation analysis confirmed an autosomal recessive inheritance pattern. The patient was 
born prematurely and was small for the gestational age (week 31; weight -3,6 SD/ height -2,2 SD). 
By three months of age, he received normal vaccinations. After he was hospitalised at the age of 
seven months due to fever and pneumonia, Pneumocystis jirovecii, metapneumovirus and 
coronavirus were revealed by respiratory secretions. Furthermore, DNAemia was noted in high 
copy numbers along with retinitis. The consequent immunological work-up depicted a phenotype 
of T-B-NK- severe combined immunodeficiency (SCID). In addition, brain magnetic resonance 
imaging (MRI) detected microcephalia and atrophic changes in the cerebellum. Due to SCID, the 
patient underwent haematopoietic stem cell transplantation (HSCT) with an umbilical cord graft  
at the age of nine months. The engraftment showed full donor chimerism with no 
manifestations of graft-versus-host disease. A post-transplant transient reactivation of 
cytomegalovirus was successfully managed by antiviral treatments. Before and after HSCT, the 
patient experienced prolonged diarrhoea and colitis-like symptoms requiring long-term total 
parenteral nutrition. The pulmonary problems remitted with recovering immunity without any sign 
of decreased liver function. After HSCT, the patient was treated by a paediatric neurologist, and 
genetic counselling was provided to the parents. No (known) family history of immunodeficiency 
or malignancy emerged. Due to the young age of the patient and the HSCT performed with 


































































































































































































5.4.2 Functional evaluation confirming the defective telomerase function  
After the identification of variants that potentially affect telomerase function, the length of the 
telomeres was investigated in all the affected subjects. All the patients presented shorter telomeres 
than the matched healthy controls, confirming the hypothesis of telomeropathy (Figure 16). In 
particular, the functional assessment of telomere length supported the clinical suspicion of DKC 
in P1.1-2, bone marrow failure in P2 and, combined with the molecular findings, the diagnosis of 





Figure 16. Relative telomere length of the patients with telomere biology disorders. 
The relative telomere length (RTL) value of each sample (Y-axis) is plotted against the individual’s age (X-axis). Solid triangles indicate the four 
TBD-patients of the study (P1.1-P3).  
Open circles represent the 113 healthy controls (age 0-83 years) used for the comparison. 
 
5.4.3 Achieving a molecular diagnosis in patients with an atypical phenotype  
The detection of TBD-causing variants in patients with seemingly distinct immune or 
haematological features highlights the effectiveness of WES to resolve atypical traits of 
monogenic syndromes. Among the cohort, only two patients (P1.1, P2) displayed mucocutaneous 
features suggestive of DKC. Moreover, in one case (P3), the genetic analysis allowed for reaching 
a prompt diagnosis of HHS, although the clinical features initially described (SCID) could have 
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determined mistargeted approaches, impairing the possibility to identify the causal variants. 
Following the molecular diagnosis, the allelic segregation of the identified disease-causing 
variant(s) should be assessed to provide genetic counselling to the families. This is especially 
relevant in the case of X-linked TBDs in which the disease-causing variant may be inherited by 
asymptomatic female carriers. 
In addition to providing a prompt molecular diagnosis, WES allowed for expanding the 
phenotypic spectrum of the studied diseases and for screening the secondary causative variants 
potentially contributing to the atypical features. From a clinical perspective, a diagnosis of 
telomeropathy in subjects with atypical presentations highlights the need to monitor other potential 
complications, such as aplastic anaemia or cytopenia. Furthermore, patients may benefit from 
treatment with anabolic steroids to improve cell counts instead of immunosuppressive therapy. 
Finally, haematopoietic stem cell transplantation can be considered for patients with severe bone 




































6 CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
 
The achievement of a means to diagnose rare genetic conditions is crucial for patients and families 
to improve genetic counselling and disease-management strategies. Identifying disease-causing 
alterations can enable precision medicine and can prevent unnecessary or potentially harmful 
interventions and treatments. Furthermore, deciphering the genetics of rare clinical phenotypes can 
provide insight into the underlying pathogenic mechanisms, increasing the understanding of 
common diseases as well. Nonetheless, not all causes of rare disorders are revealed, potentially 
leading to a ‘diagnostic odyssey’. Hence, the aim of this study was to identify the genetic causes 
of rare immunological and haematological conditions overlapping PIDs in Finnish patients lacking 
molecular characterisation. To achieve this aim, a hypothesis-free WES approach was applied for 
the routine diagnostics of PIDs, and the distribution of rare causal mutations at the population level 
was studied.  
A founder mutation in the AICDA gene accounting for all the cases of a rare primary antibody 
deficiency diagnosed in Finland thus far was identified (Hyper-IgM syndrome type 2, HIGM2). 
The causal allele is over-represented in the population as enclosed in an ancestral haplotype. The 
enrichment and the distribution of the AICDA founder mutation (all carriers originated from the 
late settlement areas) strongly reflect the genetic history of Finland and its known inhabitation 
patterns. Finns originated from small pools of founders, high isolation and several population 
bottlenecks, which caused the loss of some rare disease-causing variants and the enrichment of 
others. This phenomenon has been defined as FDH, which has caused some rare disorders to be 
more frequent in Finland than in any other country (if present). Therefore, due to the described 
prevalence of HIGM2 and the enrichment of the causal AICDA variants in Finland, AID-deficiency 
should be considered part of FDH. 
In a second study, bi-allelic ADA2 mutations causing DADA2 were identified in a set of 
patients with highly heterogeneous phenotypes. A multi-case family showed the classic DADA2 
phenotype (cutaneous Polyarteritis nodosa [cPAN], and central nervous system complications). 
All the other study subjects lacked the cPAN traits but displayed varied haematological features, 
including cytopenia and lymphoproliferation. Notably, all the studied individuals shared an 
enriched-in-Finns mutation, either as homozygous or in association with a second causal variant. 
The patients with the DADA2-vasculitic phenotype showed only the mono-allelic expression of 
the variant (driven by a splicing alteration) compared with the homozygousity occurring in patients 
with lymphoproliferation. Therefore, it is speculated that additional genetic and/or environmental 
factors could contribute to the lymphoproliferative features. Overall, the results confirm the 
relevance of WES in discerning atypical and novel phenotypes in monogenic disorders, such as 
DADA2. Moreover, the emerging extension of the phenotypic spectrum associated with ADA2 
variants suggested that varied and severe haematological symptoms should be taken into account 
when treating DADA2 patients.  
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Finally, using WES, novel disease-causing variants in telomeropathy-associated genes (DKC1, 
TERT and RTEL1 genes) were identified in three families with heterogeneous and severe immune 
and haematological phenotypes who lacked a conclusive diagnosis. A decreased telomere length 
was functionally ascertained in all cases. Notably, there was a clinical suspicion of TBD in only 
one family, and in another case, a different diagnosis was initially proposed. Overall, despite 
genetic and allelic heterogeneity, WES allowed for identifying genetic alterations in the patients, 
even in the absence of compelling pathognomonic signs. The achievement of a prompt diagnosis 
could allow for accurate genetic counselling for families, which is highly relevant due to the lack 
of efficient treatments applicable to some of the studied TBDs. Given the high proportion of novel 
variants identified, WES appears to be a more effective approach to diagnosing TBD patients than 
the NGS-panel targeting of known disease-causing variants or genes. 
Continuous technological advancements in human genomics have largely expanded the 
possibilities for genetic testing, linking life science research with clinical practice. Consequently, 
the causes of several Mendelian diseases have been identified at a rapid pace. As shown for some 
of the PIDs, the achievement of a genotype–phenotype correlation can be impeded by genetic and 
allelic heterogeneity and by the overlap of symptoms among different rare conditions. The low 
prevalence can furthermore affect the clinical description of rare novel syndromes, often not 
encompassing the overall phenotypic spectrum of the disease, which hinders the possibility to 
identify other individuals with the same phenotypes. Other limitations may arise due to the high 
rate of novel genetic alterations, which might restrict the diagnostic target of known disease causes, 
as well as due to population-specific genetic structures. The resulting diagnostic flaws might result 
even broader because of the treatment options available to patients affected by rare diseases, which 
are often limited or non-existent.  
By identifying disease-causing variants over highly heterogeneous clinical manifestations, 
WES allows for increasing the diagnostic rate of PIDs. The applied ‘genotype-first’ WES-based 
approach is an efficient method in the routine diagnostics of rare disorders, even in the absence of 
strong clinical suspicions. Moreover, the expansion of the disease-associated phenotypes, 
including atypical manifestations, represents the outset for targeted therapies for patients. 
Considering the relatively frequent occurrence of novel or familial disease-causing variants, the 
findings suggest that the application of WES (or WGS) is more effective than targeted approaches 
for specific phenotypes. However, despite the auspicious glimpse into the future of genetic testing 
applied to monogenic conditions, several limitations must be overcome to improve efficiency, 
principally at the level of the interpretation of clinical significance of genetic alterations which 
remains a bottleneck, especially in the clinical practice. The increasing availability of large-scale 
sequencing studies and tailored statistical approaches can support the identification of individuals’ 
genetic variations in the frame of clinical phenotypes and at the population level. In addition, 
functional validation and genome editing represent the frontline in improving the understanding 
of the extent of genetic alterations. Genotype-phenotype correlations can be established by the 
evaluation of the genetic variants in model systems or using patient-derived cells, such as  
fibroblasts. Among the most promising technologies, novel genomic editing tools such as 
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